FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Fredrick Hagemeister

Research Profile

Procedures

Phenomena

Recurrence

Concepts & Ideas

Disorders

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Anas Younes; Amanda Copeland; Silvana de Castro Faria; Kantharaj Ethirajulu; Michelle A Fanale; Fredrick Hagemeister; Stefan Hart; Ramesh Jayaraman; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Jorge Romaguera; Jatin Shah; Jeanette Wood; Joy Zhu
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Anas Younes; Amanda Copeland; Michelle A Fanale; Silvana de Castro Farial; Luis Fayad; Fredrick Hagemeister; Stella Kim; Larry W Kwak; John M Lambert; Rodica Morariu-Zamfir; Sattva S Neelapu; Sandrine Payrard; Jorge Romaguera; Leo I Gordon
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Michael Wang; Anas Younes; Ken H Young; Jerome Zeldis; Liang Zhang; Felipe Samaniego; Luhong Sun; Nicolaus Wagner-Bartak; Maria Badillo; Maria Bejarano; Neda Bell; Catriona Byrne; Fernando Cabanillas; Richard Champlin; Wendy Chen; Yiming Chen; Michelle A Fanale; Luis Fayad; Lei Feng; Nathan Fowler; Fredrick Hagemeister; Kimberly Hartig; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Kate J Newberry; Jorge Romaguera
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Fredrick Hagemeister (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Anas Younes; Amanda Copeland; Silvana de Castro Faria; Kantharaj Ethirajulu; Michelle A Fanale; Fredrick Hagemeister; Stefan Hart; Ramesh Jayaraman; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Jorge Romaguera; Jatin Shah; Jeanette Wood; Joy Zhu
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(33):4161-7.
2012: Anas Younes; Amanda Copeland; Michelle A Fanale; Silvana de Castro Farial; Luis Fayad; Fredrick Hagemeister; Stella Kim; Larry W Kwak; John M Lambert; Rodica Morariu-Zamfir; Sattva S Neelapu; Sandrine Payrard; Jorge Romaguera; Leo I Gordon
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2776-82.
2012: Michael Wang; Anas Younes; Ken H Young; Jerome Zeldis; Liang Zhang; Felipe Samaniego; Luhong Sun; Nicolaus Wagner-Bartak; Maria Badillo; Maria Bejarano; Neda Bell; Catriona Byrne; Fernando Cabanillas; Richard Champlin; Wendy Chen; Yiming Chen; Michelle A Fanale; Luis Fayad; Lei Feng; Nathan Fowler; Fredrick Hagemeister; Kimberly Hartig; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Kate J Newberry; Jorge Romaguera
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
The lancet oncology 2012;13(7):716-23.
2012: Anas Younes; Ying Yuan; Hubert H Chuang; Amanda R Copeland; Bouthaina Shbib Dabaja; Nam Dang; Michelle A Fanale; Lei Feng; Andre Goy; Fredrick Hagemeister; Larry W Kwak; Homer A Macapinlac; Peter McLaughlin; Sattva S Neelapu; Yasuhiro Oki; Barbara Pro; Maria A Rodriguez; Jorge Romaguera; Felipe Samaniego; Luis E Fayad
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Blood 2012;119(18):4123-8.
2012: Yasuhiro Oki; Jorge Romaguera; Amanda Copeland; Michelle Fanale; Luis E Fayad; Fredrick Hagemeister; Anas Younes
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
Blood 2012;119(9):2171-2.
2011: Deborah A Thomas; Susan O'Brien; Stefan Faderl; John T Manning; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Jeffrey Medeiros; Jorge Cortes; Hagop Kantarjian
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
Current hematologic malignancy reports 2011;6(1):58-66.
2010: Fredrick Hagemeister
Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Drugs 2010;70(3):261-72.
2009: Michael Wang; Yasuhiro Oki; Barbara Pro; Jorge Romaguera; Maria Alma Rodriguez; Felipe Samaniego; Peter McLaughlin; Fredrick Hagemeister; Sattva S Neelapu; Amanda Copeland; Barry Samuels; Evelyne M Loyer; Yuan Ji; Anas Younes
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5213-8.
2009: Bita Esmaeli; Peter McLaughlin; Barbara Pro; Felipe Samaniego; Isis Gayed; Fredrick Hagemeister; Jorge Romaguera; Fernando Cabanillas; Sattva S Neelapu; R Banay; Luis Fayad; M Wayne Saville; Larry W Kwak
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(4):709-14.
2009: Fredrick Hagemeister; George Manoukian
Bendamustine in the treatment of non-Hodgkin's lymphomas.
OncoTargets and therapy 2009;2():269-79.
2008: Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLaughlin; Maria A Rodriguez; Larry W Kwak; Yuhong Zhou; Andrew Lamb; Jorge Romaguera
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Cancer 2008;113(10):2734-41.
2008: Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Blood 2008;111(12):5530-6.
2008: Yasuhiro Oki; Barbara Pro; Luis Fayad; Jorge Romaguera; Felipe Samaniego; Fredrick Hagemeister; Sattva S Neelapu; Peter McLaughlin; Andre Goy; Anas Younes
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Cancer 2008;112(4):831-6.
2008: Paolo Anderlini; Rima M Saliba; Sandra Acholonu; Sergio Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos De Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Haematologica 2008;93(2):257-64.
2007: Nam H Dang; Luis Fayad; Peter McLaughlin; Jorge E Romaguara; Fredrick Hagemeister; Andre Goy; Sattva S Neelapu; Felipe Samaniego; Pamela L Walker; Michael Wang; Maria A Rodriguez; Ann T Tong; Barbara Pro
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
British journal of haematology 2007;138(4):502-5.
2007: Elias Jabbour; Chitra Hosing; Gregory D Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry W Kwak; Luis Fayad
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
Cancer 2007;109(12):2481-9.
2007: Luis Fayad; Fredrick Hagemeister
Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed.
Leukemia & lymphoma 2007;48(4):657-8.
2005: Fredrick Hagemeister; Fernando Cabanillas; Morton Coleman; Stephanie A Gregory; Pier Luigi Zinzani
The role of mitoxantrone in the treatment of indolent lymphomas.
The oncologist 2005;10(2):150-9.
2005: Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge Romaguera; Fredrick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David P Schenkein; Fernando Cabanillas; Alma M Rodriguez
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):667-75.
2004: Anas Younes; Barbara Pro; Michael J Robertson; Ian W Flinn; Jorge Romaguera; Fredrick Hagemeister; Nam H Dang; Paolo Fiumara; Evelyne M Loyer; Fernando Cabanillas; Peter W McLaughlin; Maria A Rodriguez; Felipe Samaniego
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5432-8.
2004: Uday Popat; Chitra Hosing; Rima M Saliba; Paolo Anderlini; Koen van Besien; Donna Przepiorka; Issa F Khouri; James L Gajewski; David F Claxton; Sergio Giralt; M Rodriguez; Jorge Romaguera; Fredrick Hagemeister; Chul Ha; J Cox; Fernando Cabanillas; Borje S Andersson; Richard E Champlin
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
Bone marrow transplantation 2004;33(10):1015-23.
2003: Anas Younes; Jorge Romaguera; Fredrick Hagemeister; Peter McLaughlin; Maria A Rodriguez; Paolo Fiumara; Andre Goy; Sima Jeha; John T Manning; Dan Jones; Lynne V Abruzzo; L Jeffrey Medeiros
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
Cancer 2003;98(2):310-4.
2002: Pamela J Schlembach; Richard B Wilder; Dan Jones; Chul Ha; Luis Fayad; Anas Younes; Fredrick Hagemeister; Mark Hess; Fernando Cabanillas; James D Cox
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Cancer journal (Sudbury, Mass.) 2002;8(5):377-83.
2001: Zhongxing Liao; Chul Ha; Maria T Vlachaki; Fredrick Hagemeister; Fernando Cabanillas; Mark Hess; Susan Tucker; James D Cox
Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
International journal of radiation oncology, biology, physics 2001;50(4):971-7.
2000: Jose Rodriguez; Peter McLaughlin; Luis Fayad; M Santiago; Mark Hess; Maria A Rodriguez; Jorge Romaguera; Fredrick Hagemeister; Andrew Lamb; Fernando Cabanillas
Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1551-6.
2000: Andreas H Sarris; A Psyrri; Fredrick Hagemeister; Jorge Romaguera; Peter McLaughlin; Maria A Rodriguez; CR Bachier; Anas Younes; Ofelia M Mesina; M Oholendt; L Jeffrey Medeiros; Barry Samuels; Laurel M Adams; Fernando Cabanillas
Infusional vinorelbine in relapsed or refractory lymphomas.
Leukemia & lymphoma 2000;39(3-4):291-9.
2000: Paolo Anderlini; Sergio Giralt; Borje Andersson; Naoto T Ueno; Issa Khouri; Sandra Acholonu; Agueda Cohen; Martin Körbling; J Manning; Jorge Romaguera; Andreas H Sarris; Fredrick Hagemeister; Peter McLaughlin; Fernando Cabanillas; Richard E Champlin
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Bone marrow transplantation 2000;26(6):615-20.
2000: N Zheng; Darren G Monckton; G Wilson; Fredrick Hagemeister; R Chakraborty; Thomas H Connor; Michael J Siciliano; Marvin L Meistrich
Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy.
Environmental and molecular mutagenesis 2000;36(2):134-45.
2000: A López-Guillermo; Fernando Cabanillas; Peter McLaughlin; T Smith; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; WC Pugh; Ming-Sheng Lee
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():137-40.
2000: Andreas H Sarris; Fredrick Hagemeister; Jorge Romaguera; Maria A Rodriguez; Peter McLaughlin; Apostolia-Maria Tsimberidou; L Jeffrey Medeiros; Barry Samuels; O Pate; M Oholendt; Andrew Lamb; C Burge; Fernando Cabanillas
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):69-72.
1999: Michele L Donato; Richard E Champlin; Koen van Besien; Martin Korbling; Fernando Cabanillas; Paolo Anderlini; J G Gajewski; Jo Lauppe; April Durett; Borje Andersson; Sergio Giralt; Issa Khouri; Fredrick Hagemeister; Jorge Romaguera; Andreas H Sarris; Peter McLaughlin; Anas Younes; Cindy Ippoliti; D A Blamble; Jeane Hester; Adrian Gee; Maria A Rodriguez
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Leukemia & lymphoma 1999;35(3-4):317-24.
1999: Donna Przepiorka; Koen van Besien; Issa Khouri; Fredrick Hagemeister; Barry Samuels; Jody Folloder; Naoto T Ueno; Jeffrey J Molldrem; RC Mehra; Martin Körbling; Sergio Giralt; James L Gajewski; Michele Donato; Karen Cleary; David F Claxton; Ira Braunschweig; Borje Andersson; Paolo Anderlini; Richard Champlin
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):527-32.
1999: A López-Guillermo; Fernando Cabanillas; Timothy J McDonnell; Peter McLaughlin; T Smith; WC Pugh; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; Ming-Sheng Lee
Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
Blood 1999;93(9):3081-7.
1998: Anas Younes; Jorge Romaguera; Ofelia M Mesina; Fredrick Hagemeister; Andreas H Sarris; Maria A Rodriguez; Peter McLaughlin; H Alejandro Preti; CR Bachier; Fernando Cabanillas
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
British journal of haematology 1998;103(3):678-83.
1998: Issa F Khouri; Jorge Romaguera; Andrew Lamb; J Lynn Palmer; WC Pugh; Martin Korbling; Fredrick Hagemeister; Barry Samuels; A Rodriguez; Sergio Giralt; Anas Younes; Donna Przepiorka; David F Claxton; Fernando Cabanillas; Richard Champlin
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3803-9.
1998: A López-Guillermo; Fernando Cabanillas; Peter McLaughlin; T Smith; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; WC Pugh; Ming-Sheng Lee
The clinical significance of molecular response in indolent follicular lymphomas.
Blood 1998;91(8):2955-60.
1998: Koen van Besien; Chul Ha; S Murphy; Peter McLaughlin; A Rodriguez; K Amin; A Forman; Jorge Romaguera; Fredrick Hagemeister; Anas Younes; CR Bachier; Andreas H Sarris; K S Sobocinski; James D Cox; Fernando Cabanillas
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
Blood 1998;91(4):1178-84.
1997: Anas Younes; JP Ayoub; Andreas H Sarris; Fredrick Hagemeister; LB North; O Pate; Peter McLaughlin; Maria A Rodriguez; Jorge Romaguera; R Kurzrock; Alejandro Preti; CR Bachier; T Smith; Fernando Cabanillas
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
British journal of haematology 1997;96(2):328-32.
1997: Anas Younes; JP Ayoub; Andreas H Sarris; LB North; O Pate; Peter McLaughlin; Maria A Rodriguez; Jorge Romaguera; Fredrick Hagemeister; CR Bachier; Alejandro Preti; Fernando Cabanillas
Paclitaxel (Taxol) for the treatment of lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():129-31.